RE:first company in history to turn Amphotericin B into a pillhttps://en.wikipedia.org/wiki/Leishmaniasis
Oral B Amphotericin will prevent this terrible disease and alleviate the suffering of many people.
ICO is now attracting the attention of the market because of positive trials and testing on human subjects. I think that any deal flow will be announced after the upcoming AGM, and that ICO has been under pressure in advance of a hostile takeover bid, so the need for a poison pill provision may be necessary in order to maximize the inherent value of this company.
Oral B Amphtericin is only one of the items streaming through the product pipeline.
The cost of this drug orally could prove to be a big factor if it becomes very economical for the patient as compared to the higher cost of the injectable dose today, which bodes well for taking market share away from competitors in the pharmceutical industry.
Therefore, the fair value of ICO is many multiples of it`s current stock price and could conceivably exceed expectations on the upside. A ten-bagger would yield a share price of about 55 cents, but I think this is too low a valuation for what is likely to be a mutil billion dollar market share. So, conservatively, this stock ought to be anywhere from a 50 to 100 bagger, or roughly 3 to 5 dollars based just on Oral B Amphotericin. ICO is about to become a premier biotech stock of the 21st century. Congratulations and thanks to Andrew Rae and employees of ICO.
DOC.